Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis

IsraelEnrolling By InvitationPHASE2, PHASE3

Conditions

Generalized Myasthenia Gravis · gMG

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Ann and Robert H Lurie Children's Hospital of Chicago - Main Hospital, Chicago, Illinois, United States

  • Atrium Health Neurology Specialty Care, Charlotte, North Carolina, United States

  • University of Virginia (UVA) Health - Developmental Pediatrics Clinic, Charlottesville, Virginia, United States

  • Universitair Ziekenhuis Antwerpen, Edegem, Belgium

  • UZ Gent, Ghent, Belgium

  • Childrens Hospital of Eastern Ontario, Ottawa, Canada

  • AP-HM- Hôpital de La Timone, Marseille, France

  • Universitätsklinikum Essen, Essen, Germany

  • Hadassah Medical Center- Ein Kerem, Jerusalem, Israel

  • Leids Universitair Medisch Centrum, Leiden, Netherlands

  • Uniwersyteckie Centrum Kliniczne w Gdansku, Gdansk, Poland

  • Wielospecjalistyczna Poradnia Lekarska Synapsis, Katowice, Poland

  • Centralny Szpital Kliniczny - Uniwersyteckie Centrum Kliniczne WUM, Warsaw, Poland

  • Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain

  • Great Ormand Street Hospital for Children NHS Foundation Trust - Great Ormond Street Hospital - Pediatric Neurology, London, United Kingdom

  • Oxford University Hospitals NHS Foundation Trust - John Radcliffe Hospital Children's Hospital, Oxford, United Kingdom